bevyxxa Drug Patent Profile
✉ Email this page to a colleague
When do Bevyxxa patents expire, and what generic alternatives are available?
Bevyxxa is a drug marketed by Portola Pharms Inc and is included in one NDA. There are five patents protecting this drug.
This drug has sixty-seven patent family members in twenty-six countries.
The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
DrugPatentWatch® Generic Entry Outlook for Bevyxxa
Bevyxxa was eligible for patent challenges on June 23, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 29, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for bevyxxa?
- What are the global sales for bevyxxa?
- What is Average Wholesale Price for bevyxxa?
Summary for bevyxxa
| International Patents: | 67 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 84 |
| Patent Applications: | 420 |
| Drug Prices: | Drug price information for bevyxxa |
| DailyMed Link: | bevyxxa at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for bevyxxa
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for bevyxxa
bevyxxa is protected by six US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of bevyxxa is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting bevyxxa
Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: INHIBITING COAGULATION
Methods of using crystalline forms of a salt of a factor Xa inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
Methods of using crystalline forms of a salt of a factor Xa inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PROPHYLAXIS OF VENOUS THROMBOSIS
Methods of synthesizing factor Xa inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PROPHYLAXIS OF PULMONARY EMBOLISM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for bevyxxa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | ⤷ Sign Up | ⤷ Sign Up |
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | ⤷ Sign Up | ⤷ Sign Up |
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for bevyxxa
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Portola Pharma UK Limited | Dexxience | betrixaban | EMEA/H/C/004309 Prevention of venous thromboembolism |
Refused | no | no | no | 2018-09-20 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for bevyxxa
When does loss-of-exclusivity occur for bevyxxa?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 07333377
Patent: Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 71502
Patent: FORMULATIONS DE DOSES UNITAIRES ET PROCEDES DE TRAITEMENT D'UNE THROMBOSE AVEC UN INHIBITEUR ORAL DU FACTEUR XA (UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Patent: 13963
Patent: FORMULATIONS DE DOSES UNITAIRES ET PROCEDES DE TRAITEMENT D'UNE THROMBOSE AVEC UN INHIBITEUR ORAL DU FACTEUR XA (UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1652136
Patent: Unit dose formulations and methods of treating thrombosis with an oral factor XA inhibitor
Estimated Expiration: ⤷ Sign Up
Patent: 5193799
Patent: Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 20933
Patent: FORMULACIONES DE DOSIS UNITARIA Y METDODS PARA EL TRATAMIENTO DE LA TROMBOSIS CON UN INHIBIDOR ORAL DEL FACROR XA
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 914
Patent: UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 099501
Patent: FORMULACIONES DE DOSIS UNITARIA Y MÉTODOS PARA EL TRATAMIENTO DE LA TROMBOSIS CON UN INHIBIDOR ORAL DEL FACTOR XA
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 01760
Patent: FORMULATIONS DE DOSES UNITAIRES ET PROCÉDÉS DE TRAITEMENT D'UNE THROMBOSE AVEC UN INHIBITEUR ORAL DU FACTEUR XA (UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 34031
Patent: UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 9219
Patent: בטריקסאבאן או מלחיו, לשימוש בעיכוב קרישת דם (Betrixaban or salt thereof for use in inhibiting blood coagulation)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 086
Patent: FORMULATIONS DE DOSES UNITAIRES ET PROCEDES DE TRAITEMENT D'UNE THROMBOSE AVEC UN INHIBITEUR ORAL DU FACTEUR XA.
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 8180
Patent: UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR
Estimated Expiration: ⤷ Sign Up
Nicaragua
Patent: 0900145
Patent: FORMULACIONES DE DOSIS UNITARIA Y METODOS PARA EL TRATAMIENTO DE LA TROMBOSIS CON UN INHIBIDOR ORAL DEL FACTOR XA.
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 01760
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 52484
Patent: СТАНДАРТНЫЕ ЛЕКАРСТВЕННЫЕ ПРЕПАРАТЫ И СПОСОБЫ ЛЕЧЕНИЯ ТРОМБОЗА ПЕРОРАЛЬНЫМ ВВЕДЕНИЕМ ИНГИБИТОРА ФАКТОРА ХА (STANDARD DRUG PREPARATIONS AND METHODS OF TREATING THROMBOSIS BY ORAL ADMINISTRATION OF FACTOR XA INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Patent: 09126147
Patent: СТАНДАРТНЫЕ ЛЕКАРСТВЕННЫЕ ПРЕПАРАТЫ И СПОСОБЫ ЛЕЧЕНИЯ ТРОМБОЗА ПЕРОРАЛЬНЫМ ВВЕДЕНИЕМ ИНГИБИТОРА ФАКТОРА Ха
Estimated Expiration: ⤷ Sign Up
Patent: 12104816
Patent: СТАНДАРТНЫЕ ЛЕКАРСТВЕННЫЕ ПРЕПАРАТЫ И СПОСОБЫ ЛЕЧЕНИЯ ТРОМБОЗА ПЕРОРАЛЬНЫМ ВВЕДЕНИЕМ ИНГИБИТОРА ФАКТОРА ХА
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201504425S
Patent: UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0904758
Patent: Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1472765
Estimated Expiration: ⤷ Sign Up
Patent: 090107499
Patent: Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 09090
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering bevyxxa around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 1948608 | ⤷ Sign Up | |
| China | 101304971 | Pharmaceutical salts and polymorphs of n- (5-chl0r0-2-pyridinyl) -2- [ [4- [ (dimethylamino) iminomethyl] benzoyl] amino] -5-meth oxy-benzamide, a factor xa inhibitor | ⤷ Sign Up |
| Norway | 20021229 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
